{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T01:19:23Z","timestamp":1788311963345,"version":"build-2803163510"},"reference-count":79,"publisher":"BMJ","issue":"9","license":[{"start":{"date-parts":[[2021,9,17]],"date-time":"2021-09-17T00:00:00Z","timestamp":1631836800000},"content-version":"unspecified","delay-in-days":16,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000276","name":"Department of Health and Social Care","doi-asserted-by":"publisher","award":["IS-RRT-1015-001"],"award-info":[{"award-number":["IS-RRT-1015-001"]}],"id":[{"id":"10.13039\/501100000276","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Glob Health"],"accepted":{"date-parts":[[2021,8,29]]},"published-print":{"date-parts":[[2021,9]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>COVID-19 vaccines are now being distributed to low- and middle-income countries (LMICs), with global urgency surrounding national vaccination plans. LMICs have significant experience implementing vaccination campaigns to respond to epidemic threats but are often hindered by chronic health system challenges. We sought to identify transferable lessons for COVID-19 vaccination from the rollout of three vaccines that targeted adult groups in Africa and South America: MenAfriVac (meningitis A); 17D (yellow fever) and rVSV-ZEBOV (Ebola virus disease).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a rapid literature review and 24 semi-structured interviews with technical experts who had direct implementation experience with the selected vaccines in Africa and South America. We identified barriers, enablers, and key lessons from the literature and from participants\u2019 experiences. Interview data were analysed thematically according to seven implementation domains.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Participants highlighted multiple components of vaccination campaigns that are instrumental for achieving high coverage. Community engagement is an essential and effective tool, requiring dedicated time, funding and workforce. Involving local health workers is a key enabler, as is collaborating with community leaders to map social groups and tailor vaccination strategies to their needs. Vaccination team recruitment and training strategies need to be enhanced to support vaccination campaigns. Although recognised as challenging, integrating vaccination campaigns with other routine health services can be highly beneficial if well planned and coordinated across health programmes and with communities.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>As supplies of COVID-19 vaccines become available to LMICs, countries need to prepare to efficiently roll out the vaccine, encourage uptake among eligible groups and respond to potential community concerns. Lessons from the implementation of these three vaccines that targeted adults in LMICs can be used to inform best practice for COVID-19 and other epidemic vaccination campaigns.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjgh-2021-006951","type":"journal-article","created":{"date-parts":[[2021,9,17]],"date-time":"2021-09-17T12:01:41Z","timestamp":1631880101000},"page":"e006951","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":21,"title":["\u2018Learn from the lessons and don\u2019t forget them\u2019: identifying transferable lessons for COVID-19 from meningitis A, yellow fever and Ebola virus disease vaccination campaigns"],"prefix":"10.1136","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0673-3649","authenticated-orcid":false,"given":"Julie","family":"Collins","sequence":"first","affiliation":[{"name":"UK Public Health Rapid Support Team, London School of Hygiene & Tropical Medicine\/Public Health England, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosie","family":"Westerveld","sequence":"additional","affiliation":[{"name":"Department of Infectious Disease Epidemiology, Faculty of Epidemiology and Population Health, London School of Hygiene & Tropical Medicine, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7747-1482","authenticated-orcid":false,"given":"Kate A","family":"Nelson","sequence":"additional","affiliation":[{"name":"Department of Infectious Disease Epidemiology, Faculty of Epidemiology and Population Health, London School of Hygiene & Tropical Medicine, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5327-6348","authenticated-orcid":false,"given":"Hana","family":"Rohan","sequence":"additional","affiliation":[{"name":"UK Public Health Rapid Support Team, London School of Hygiene & Tropical Medicine\/Public Health England, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1541-6637","authenticated-orcid":false,"given":"Hilary","family":"Bower","sequence":"additional","affiliation":[{"name":"UK Public Health Rapid Support Team, London School of Hygiene & Tropical Medicine\/Public Health England, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siobhan","family":"Lazenby","sequence":"additional","affiliation":[{"name":"Gates Ventures, Kirkland, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gloria","family":"Ikilezi","sequence":"additional","affiliation":[{"name":"Gates Ventures, Kirkland, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Bartlein","sequence":"additional","affiliation":[{"name":"Gates Ventures, Kirkland, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel G","family":"Bausch","sequence":"additional","affiliation":[{"name":"UK Public Health Rapid Support Team, London School of Hygiene & Tropical Medicine\/Public Health England, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0004-6167","authenticated-orcid":false,"given":"David S","family":"Kennedy","sequence":"additional","affiliation":[{"name":"UK Public Health Rapid Support Team, London School of Hygiene & Tropical Medicine\/Public Health England, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2021,9,17]]},"reference":[{"key":"2025073015270820000_6.9.e006951.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00424-4"},{"key":"2025073015270820000_6.9.e006951.2","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/S2666-5247(20)30226-3","article-title":"COVID-19 vaccines: the pandemic will not end overnight","volume":"2","year":"2021","journal-title":"Lancet Microbe"},{"key":"2025073015270820000_6.9.e006951.3","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m4750"},{"key":"2025073015270820000_6.9.e006951.4","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/s41562-021-01122-8","article-title":"A global database of COVID-19 vaccinations","volume":"5","author":"Mathieu","year":"2021","journal-title":"Nat Hum Behav"},{"key":"2025073015270820000_6.9.e006951.5","unstructured":"World Health Organization . COVAX Announces additional deals to access promising COVID-19 vaccine candidates; plans global rollout starting Q1 2021, 2020. Available: https:\/\/www.who.int\/news\/item\/18-12-2020-covax-announces-additional-deals-to-access-promising-covid-19-vaccine-candidates-plans-global-rollout-starting-q1-2021 [Accessed 25 Jan 2021]."},{"key":"2025073015270820000_6.9.e006951.6","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2019.1574224"},{"key":"2025073015270820000_6.9.e006951.7","doi-asserted-by":"crossref","DOI":"10.1038\/s41541-021-00323-6","article-title":"Access to and equitable distribution of COVID-19 vaccine in low-income countries","volume":"6","author":"Acharya","year":"2021","journal-title":"NPJ Vaccines"},{"key":"2025073015270820000_6.9.e006951.8","doi-asserted-by":"crossref","DOI":"10.1186\/s12889-020-09169-4","article-title":"Barriers to childhood immunization in sub-Saharan Africa: a systematic review","volume":"20","author":"Bangura","year":"2020","journal-title":"BMC Public Health"},{"key":"2025073015270820000_6.9.e006951.9","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-017-4020-6"},{"key":"2025073015270820000_6.9.e006951.10","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008145.pub3"},{"key":"2025073015270820000_6.9.e006951.11","unstructured":"World Health Organization . Global Ebola Vaccine Implementation Team (GEVIT) Practical guidance on the use of Ebola vaccine in an outbreak response, 2016."},{"key":"2025073015270820000_6.9.e006951.12","unstructured":"Ebola Vaccine Deployment, Acceptance and Compliance (EBODAC) Consortium . Ebola vaccine communication, community engagement and compliance management (3C) gap analysis tool, 2019."},{"key":"2025073015270820000_6.9.e006951.13","unstructured":"World Health Organization, UNICEF . Guidance on developing a national deployment and vaccination plan for COVID-19 vaccines: interim guidance, 2020."},{"key":"2025073015270820000_6.9.e006951.14","doi-asserted-by":"crossref","first-page":"S391","DOI":"10.1093\/cid\/civ593","article-title":"From epidemic meningitis vaccines for Africa to the meningitis vaccine project","volume":"61 Suppl 5","author":"Aguado","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2025073015270820000_6.9.e006951.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2014.09.031"},{"key":"2025073015270820000_6.9.e006951.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2012.09.008"},{"key":"2025073015270820000_6.9.e006951.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2014.01.038"},{"key":"2025073015270820000_6.9.e006951.18","doi-asserted-by":"crossref","first-page":"B40","DOI":"10.1016\/j.vaccine.2011.12.073","article-title":"Effectively introducing a new meningococcal a conjugate vaccine in Africa: the Burkina Faso experience","volume":"30 Suppl 2","author":"Djingarey","year":"2012","journal-title":"Vaccine"},{"key":"2025073015270820000_6.9.e006951.19","doi-asserted-by":"crossref","first-page":"S442","DOI":"10.1093\/cid\/civ671","article-title":"Risk assessment and meningococcal a conjugate vaccine introduction in Africa: the district prioritization tool","volume":"61 Suppl 5","author":"Cibrelus","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2025073015270820000_6.9.e006951.20","doi-asserted-by":"crossref","first-page":"D74","DOI":"10.1016\/j.vaccine.2012.01.080","article-title":"The expanded programme on immunization: a lasting legacy of smallpox eradication","volume":"29 Suppl 4","author":"Okwo-Bele","year":"2011","journal-title":"Vaccine"},{"key":"2025073015270820000_6.9.e006951.21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0063605"},{"key":"2025073015270820000_6.9.e006951.22","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1016\/S1473-3099(20)30239-5","article-title":"Meningococcal carriage 7 years after introduction of a serogroup a meningococcal conjugate vaccine in Burkina Faso: results from four cross-sectional carriage surveys","volume":"20","author":"Mbaeyi","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"2025073015270820000_6.9.e006951.23","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)61612-8"},{"key":"2025073015270820000_6.9.e006951.24","doi-asserted-by":"crossref","DOI":"10.1186\/s12889-020-8347-z","article-title":"Health workers' perceptions and challenges in implementing meningococcal serogroup a conjugate vaccine in the routine childhood immunization schedule in Burkina Faso","volume":"20","author":"Nkwenkeu","year":"2020","journal-title":"BMC Public Health"},{"key":"2025073015270820000_6.9.e006951.25","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiz308"},{"key":"2025073015270820000_6.9.e006951.26","doi-asserted-by":"crossref","first-page":"S467","DOI":"10.1093\/cid\/civ499","article-title":"Public health impact after the introduction of PsA-TT: the first 4 years","volume":"61 Suppl 5","author":"Diomand\u00e9","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2025073015270820000_6.9.e006951.27","doi-asserted-by":"crossref","first-page":"S451","DOI":"10.1093\/cid\/civ493","article-title":"Communication challenges during the development and introduction of a new meningococcal vaccine in Africa","volume":"61 Suppl 5","author":"Berlier","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2025073015270820000_6.9.e006951.28","doi-asserted-by":"crossref","first-page":"S434","DOI":"10.1093\/cid\/civ551","article-title":"Introduction and Rollout of a new group A meningococcal conjugate vaccine (PsA-TT) in African meningitis belt countries, 2010-2014","volume":"61 Suppl 5","author":"Djingarey","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2025073015270820000_6.9.e006951.29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0003838"},{"key":"2025073015270820000_6.9.e006951.30","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/s41541-020-0204-7","article-title":"Applying lessons from the Ebola vaccine experience for SARS-CoV-2 and other epidemic pathogens","volume":"5","author":"Wolf","year":"2020","journal-title":"NPJ Vaccines"},{"key":"2025073015270820000_6.9.e006951.31","doi-asserted-by":"crossref","first-page":"S48","DOI":"10.1093\/infdis\/jix336","article-title":"Rapid establishment of a cold chain capacity of -60\u00b0C or Colder for the strive Ebola vaccine trial during the Ebola outbreak in Sierra Leone","volume":"217","author":"Jusu","year":"2018","journal-title":"J Infect Dis"},{"key":"2025073015270820000_6.9.e006951.32","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1093\/infdis\/jiy020","article-title":"The Sierra Leone trial to introduce a vaccine against Ebola: an evaluation of rVSV\u2206G-ZEBOV-GP vaccine tolerability and safety during the West Africa Ebola outbreak","volume":"217","author":"Samai","year":"2018","journal-title":"J Infect Dis"},{"key":"2025073015270820000_6.9.e006951.33","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aat0360"},{"key":"2025073015270820000_6.9.e006951.34","doi-asserted-by":"crossref","first-page":"7183","DOI":"10.1016\/j.vaccine.2017.09.094","article-title":"Data management of clinical trials during an outbreak of Ebola virus disease","volume":"37","author":"Hossmann","year":"2019","journal-title":"Vaccine"},{"key":"2025073015270820000_6.9.e006951.35","doi-asserted-by":"crossref","first-page":"7165","DOI":"10.1016\/j.vaccine.2019.09.094","article-title":"Factors influencing participation in an Ebola vaccine trial among front-line workers in guinea","volume":"37","author":"Grantz","year":"2019","journal-title":"Vaccine"},{"key":"2025073015270820000_6.9.e006951.36","doi-asserted-by":"crossref","first-page":"7171","DOI":"10.1016\/j.vaccine.2018.09.009","article-title":"Safety of the rVSV ZEBOV vaccine against Ebola Zaire among frontline workers in guinea","volume":"37","author":"Juan-Giner","year":"2019","journal-title":"Vaccine"},{"key":"2025073015270820000_6.9.e006951.37","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1586\/14760584.2015.1064313","article-title":"Global lessons from Nigeria's ebolavirus control strategy","volume":"14","author":"Elemuwa","year":"2015","journal-title":"Expert Rev Vaccines"},{"key":"2025073015270820000_6.9.e006951.38","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1080\/17441692.2019.1632368","article-title":"Conceptions within misconceptions: Pluralisms in an Ebola vaccine trial in West Africa","volume":"15","author":"Alenichev","year":"2020","journal-title":"Glob Public Health"},{"key":"2025073015270820000_6.9.e006951.39","doi-asserted-by":"crossref","DOI":"10.1186\/s12910-016-0094-4","article-title":"Ebola vaccine development plan: ethics, concerns and proposed measures","volume":"17","author":"Folayan","year":"2016","journal-title":"BMC Med Ethics"},{"key":"2025073015270820000_6.9.e006951.40","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines7040179","article-title":"Disease resurgence, production capability issues and safety concerns in the context of an aging population: is there a need for a new yellow fever vaccine?","volume":"7","author":"Tomashek","year":"2019","journal-title":"Vaccines"},{"key":"2025073015270820000_6.9.e006951.41","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1001\/jama.2017.14258","article-title":"Vaccination challenges in confronting the resurgent threat from yellow fever","volume":"318","author":"Chen","year":"2017","journal-title":"JAMA"},{"key":"2025073015270820000_6.9.e006951.42","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1056\/NEJMp1803433","article-title":"Fractional-Dose yellow fever vaccination \u2014 advancing the evidence base","volume":"379","author":"Vannice","year":"2018","journal-title":"N Engl J Med Overseas Ed"},{"key":"2025073015270820000_6.9.e006951.43","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1056\/NEJMp1606997","article-title":"Yellow fever in Angola and beyond \u2014 the problem of vaccine supply and demand","volume":"375","author":"Barrett","year":"2016","journal-title":"N Engl J Med Overseas Ed"},{"key":"2025073015270820000_6.9.e006951.44","doi-asserted-by":"crossref","DOI":"10.1590\/0074-02760180278","article-title":"Yellow fever outbreak in Brazil: the puzzle of rapid viral spread and challenges for immunisation","volume":"113","author":"Possas","year":"2018","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"2025073015270820000_6.9.e006951.45","doi-asserted-by":"publisher","DOI":"10.4161\/hv.22982"},{"key":"2025073015270820000_6.9.e006951.46","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0007661","article-title":"Vaccination coverage in the context of the emerging yellow fever threat in French Guiana","volume":"13","author":"Flamand","year":"2019","journal-title":"PLoS Negl Trop Dis"},{"key":"2025073015270820000_6.9.e006951.47","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0006409","article-title":"Community knowledge, attitudes and practices on yellow fever in South Omo area, southern Ethiopia","volume":"12","author":"Legesse","year":"2018","journal-title":"PLoS Negl Trop Dis"},{"key":"2025073015270820000_6.9.e006951.48","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ijid.2018.11.324","article-title":"Vaccine stockpile governance through partnership: the International coordination group on emergency vaccine provision and its impacts","volume":"79","author":"Nguyen","year":"2019","journal-title":"Int J Infect Dis"},{"key":"2025073015270820000_6.9.e006951.49","doi-asserted-by":"crossref","DOI":"10.1186\/s13104-015-1109-9","article-title":"Vaccine storage and cold chain monitoring in the North West region of Cameroon: a cross sectional study","volume":"8","author":"Yakum","year":"2015","journal-title":"BMC Res Notes"},{"key":"2025073015270820000_6.9.e006951.50","doi-asserted-by":"crossref","first-page":"3747","DOI":"10.1016\/j.vaccine.2018.05.062","article-title":"Challenges of cold chain quality for routine EPI in south-west Burkina-Faso: an assessment using automated temperature recording devices","volume":"36","author":"Sow","year":"2018","journal-title":"Vaccine"},{"key":"2025073015270820000_6.9.e006951.51","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1586\/14760584.2013.855612","article-title":"Introducing new vaccines in developing countries","volume":"12","author":"Kochhar","year":"2013","journal-title":"Expert Rev Vaccines"},{"key":"2025073015270820000_6.9.e006951.52","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-044111"},{"key":"2025073015270820000_6.9.e006951.53","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgh-2020-003229"},{"key":"2025073015270820000_6.9.e006951.54","doi-asserted-by":"crossref","DOI":"10.1186\/s12992-018-0420-3","article-title":"A conceptual framework for training of trainers (TOT) interventions in global health","volume":"14","author":"Mormina","year":"2018","journal-title":"Global Health"},{"key":"2025073015270820000_6.9.e006951.55","unstructured":"World Health Organization . Interim recommendations for use of the Pfizer\u2013BioNTech COVID-19 vaccine, BNT162b2 under emergency use listing 2021."},{"key":"2025073015270820000_6.9.e006951.56","doi-asserted-by":"publisher","DOI":"10.1093\/heapol\/czx039"},{"key":"2025073015270820000_6.9.e006951.57","doi-asserted-by":"crossref","first-page":"e901","DOI":"10.1016\/S2214-109X(20)30229-1","article-title":"Early estimates of the indirect effects of the COVID-19 pandemic on maternal and child mortality in low-income and middle-income countries: a modelling study","volume":"8","author":"Roberton","year":"2020","journal-title":"Lancet Glob Health"},{"key":"2025073015270820000_6.9.e006951.58","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgh-2021-005031"},{"key":"2025073015270820000_6.9.e006951.59","unstructured":"World Health Organization . AstraZeneca ChAdOx1-S\/nCoV-19 [recombinant], COVID-19 vaccine, 2021."},{"key":"2025073015270820000_6.9.e006951.60","unstructured":"World Health Organization . Janssen Ad26.COV2-S [recombinant], COVID-19 vaccine, 2021."},{"key":"2025073015270820000_6.9.e006951.61","unstructured":"World Health Organization . Moderna mRNA-1273, COVID-19 vaccine, 2020."},{"key":"2025073015270820000_6.9.e006951.62","unstructured":"World Health Organization . Pfizer\/BioNTech COMIRNATY\u00ae, COVID-19 vaccine, 2021."},{"key":"2025073015270820000_6.9.e006951.63","unstructured":"World Health Organization . Sinopharm [Vero Cell]- Inactivated, COVID-19 vaccine, 2021."},{"key":"2025073015270820000_6.9.e006951.64","unstructured":"World Health Organization . Background document on the inactivated vaccine Sinovac-CoronaVac against COVID-19, 2021."},{"key":"2025073015270820000_6.9.e006951.65","first-page":"726","article-title":"Single-dose versus multi-dose vaccine vials for immunization programmes in developing countries","volume":"81","author":"Drain","year":"2003","journal-title":"Bull World Health Organ"},{"key":"2025073015270820000_6.9.e006951.66","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2020.07.012"},{"key":"2025073015270820000_6.9.e006951.67","first-page":"279","article-title":"Adapting the Incident Management System for response to health emergencies - early experience of WHO","volume":"93","author":"Richard","year":"2018","journal-title":"Weekly epidemiological record"},{"key":"2025073015270820000_6.9.e006951.68","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2016.00254","article-title":"Incident management systems are essential for effective coordination of large disease outbreaks: perspectives from the coordination of the Ebola outbreak response in Sierra Leone","volume":"4","author":"Olu","year":"2016","journal-title":"Front Public Health"},{"key":"2025073015270820000_6.9.e006951.69","article-title":"Psychological impact of COVID-19 pandemic on frontline health workers in low- and middle-income countries","volume":"28","author":"Deng","year":"2020","journal-title":"Harv Public Health Rev"},{"key":"2025073015270820000_6.9.e006951.70","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.vaccine.2019.10.088","article-title":"Barriers to vaccination in Latin America: a systematic literature review","volume":"38","author":"Guzman-Holst","year":"2020","journal-title":"Vaccine"},{"key":"2025073015270820000_6.9.e006951.71","doi-asserted-by":"publisher","DOI":"10.2471\/BLT.11.08986"},{"key":"2025073015270820000_6.9.e006951.72","unstructured":"World Health Organization . Vaccines and vaccination against yellow fever. WHO position paper, 2013."},{"key":"2025073015270820000_6.9.e006951.73","unstructured":"World Health Organization . Meningococcal vaccines: WHO position paper, 2011."},{"key":"2025073015270820000_6.9.e006951.74","first-page":"57","article-title":"WHO position paper, meningococcal a conjugate vaccine: updated guidance, February 2015","volume":"36","year":"2018","journal-title":"Vaccine"},{"key":"2025073015270820000_6.9.e006951.75","unstructured":"World Health Organization . WHO prequalifies Ebola vaccine, paving the way for its use in high-risk countries, 2019. Available: https:\/\/www.who.int\/news\/item\/12-11-2019-who-prequalifies-ebola-vaccine-paving-the-way-for-its-use-in-high-risk-countries [Accessed 19 Apr 2021]."},{"key":"2025073015270820000_6.9.e006951.76","doi-asserted-by":"crossref","first-page":"85","DOI":"10.2217\/fmb-2019-0237","article-title":"Safety, immunogenicity and risk-benefit analysis of rVSV-\u0394G-ZEBOV-GP (V920) Ebola vaccine in phase I-III clinical trials across regions","volume":"15","author":"Bache","year":"2020","journal-title":"Future Microbiol"},{"key":"2025073015270820000_6.9.e006951.77","unstructured":"World Health Organization . Ebola virus disease: vaccines, 2020. Available: https:\/\/www.who.int\/news-room\/q-a-detail\/ebola-vaccines [Accessed 11 Jul 2021]."},{"key":"2025073015270820000_6.9.e006951.78","unstructured":"World Health Organization . Community engagement: a health promotion guide for universal health coverage in the hands of the people, 2020."},{"key":"2025073015270820000_6.9.e006951.79","unstructured":"World Health Organization . Communication for behavioural impact: a toolkit for behavioural and social communication in outbreak response, 2012."}],"container-title":["BMJ Global Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjgh-2021-006951","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T22:27:17Z","timestamp":1753914437000},"score":1,"resource":{"primary":{"URL":"https:\/\/gh.bmj.com\/lookup\/doi\/10.1136\/bmjgh-2021-006951"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":79,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2021,9,17]]},"published-print":{"date-parts":[[2021,9]]}},"alternative-id":["10.1136\/bmjgh-2021-006951"],"URL":"https:\/\/doi.org\/10.1136\/bmjgh-2021-006951","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.07.15.21260439","asserted-by":"object"}]},"ISSN":["2059-7908"],"issn-type":[{"value":"2059-7908","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9]]}}}